Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
Akshay SoodJan K RudzinskiCraig V LabbatePatrick J HensleyKelly K BreeCharles C GuoOmar AlhalabiMatthew T CampbellArlene O Siefker-RadtkeNeema NavaiColin P N DinneyJianjun GaoAshish M KamatPublished in: The Journal of urology (2023)
The PV-BCa is a disease with high lethality. Despite multimodal treatment, a vast majority of patients develop atypical intraperitoneal metastasis soon after therapy and rapidly succumb to it. Clinical trials evaluating utility of hyperthermic intraperitoneal chemotherapy (HIPEC) and/or immunotherapy may be warranted in this high-risk population.
Keyphrases
- end stage renal disease
- clinical trial
- chronic kidney disease
- ejection fraction
- newly diagnosed
- dendritic cells
- peritoneal dialysis
- small cell lung cancer
- squamous cell carcinoma
- stem cells
- randomized controlled trial
- prognostic factors
- radiation therapy
- patient reported outcomes
- type diabetes
- molecular dynamics
- mesenchymal stem cells
- immune response
- skeletal muscle
- pain management
- patient reported
- smoking cessation
- lymph node metastasis
- cell therapy